康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CXO 康休

退市 01-15 16:00:00 EST

65.60

+0.00

0.00%

最高65.60	最低65.60	成交量0.00
今开65.60	昨收65.60	日振幅0.00%
总市值127.60亿	流通市值126.27亿	总股本1.95亿
成交额0.00	换手率0.00%	流通股本1.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CXO","market":"US","secType":"STK","nameCN":"康休","latestPrice":65.6,"timestamp":1610744400000,"preClose":65.6,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":192489259,"shares":194506801,"eps":-52.266872,"marketStatus":"退市","change":0,"latestTime":"01-15 16:00:00 EST","open":65.6,"high":65.6,"low":65.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-52.266872,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788163200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1186113600000,"exchange":"NYSE","adjPreClose":65.6,"dividendRate":0.011052,"volumeRatio":0},"requestUrl":"/m/hq/s/CXO","defaultTab":"news","newsList":[{"id":"2662766810","title":"CXO今天也是支棱起来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766810","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662766810?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:11","pubTimestamp":1787706660,"startTime":"0","endTime":"0","summary":"来源：硬核姬老板MACD金叉信号形成，这些股涨势不错！","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-26/doc-inipqxha2247730.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662731118","title":"中报再点火，CXO全线爆发！药明合联、凯莱英绩后狂飙，港股通医疗ETF（159137）爆量大涨，成交额激增超300%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662731118","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662731118?lang=zh_cn&edition=full","pubTime":"2026-08-25 19:41","pubTimestamp":1787658060,"startTime":"0","endTime":"0","summary":"CXO含量超50%的港股通医疗ETF华宝全天单边上行，日线强势“阳包阴”！24日，药明合联、凯莱英双双发布2026年中报，上半年经调整归母净利润均实现同比两位数增长，增速分别为37.4%、12.9%。药明合联上半年未完成总订单达22亿美元，同比大幅增长62.2%；凯莱英公司在手订单总额16.73亿美元，较去年同期增长53.77%，新签订单同比增长54.59%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-25/doc-inipprnk9691167.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FLHK","06821","CXO","159828","BK1191","159137","LU1328615791.USD","LU2488822045.USD","SG9999014674.SGD","BK1141","BK0132","02268","002821","BK0239","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662004362","title":"港股异动 | CRO概念股涨幅居前 海外CXO业绩普遍超预期 机构指全球需求复苏确认","url":"https://stock-news.laohu8.com/highlight/detail?id=2662004362","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662004362?lang=zh_cn&edition=full","pubTime":"2026-08-25 10:20","pubTimestamp":1787624451,"startTime":"0","endTime":"0","summary":"消息面上，IQVIA、Medpace、Lonza、三星生物等海外CXO龙头业绩密集披露，订单端强势反转，多家上调全年指引。湘财证券认为，近期CXO整体表现亮眼是全球医药融资回暖下产业基本面持续向好的全球性的趋势，中国CXO相关公司具备工程师红利将充分享受产业红利，在全球产业向好的趋势下持续性预计将较强。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","WX","LU1880383366.USD","BK1521","LU0307460666.USD","03347","LU0052750758.USD","BK4588","LU0516423174.USD","LU0856984785.SGD","BK1141","LU0320764599.SGD","LU0348825331.USD","LU0181495838.USD","LU0417516738.SGD","01548","VXUS","LU0572944931.SGD","LU2039709279.SGD","LU1242518931.SGD","LU0516422440.USD","LU1688375341.USD","06821","LU0140636845.USD","BK4585","KURE","BK1576","LU0359201612.USD","LU0456827905.SGD","LU0417516902.SGD","BK1583","BK1610","LU0128526141.USD","LU0029874061.USD","CXO","LU0979878070.USD","LU1794554557.SGD","LU0051755006.USD","LU0708995583.HKD","LU0327786744.USD","02269","LU0823426308.USD","HK0000320223.HKD","LU0516422952.EUR","LU0823426480.USD","LU3063872942.SGD","KCAI","LU1242518857.USD","LU0456846285.SGD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200320","title":"医药外包概念盘初普升 凯莱英（06821）涨6.21% 机构指CXO行业景气上行逻辑不断夯实","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200320","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662200320?lang=zh_cn&edition=full","pubTime":"2026-08-25 09:57","pubTimestamp":1787623040,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初普升，截至发稿，凯莱英 涨6.21%，金斯瑞生物科技涨4.78%，药明生物涨2.22%，维亚生物涨1.67%，泰格医药涨1.05%。消息面上，国金证券表示，CXO行业景气度持续向上，全球生物医药投融资回暖带动创新药研发投入提速，海内外龙头订单与业绩逐步兑现，行业景气上行逻辑不断夯实。头部CXO企业也主动融合AI能力，迭代实验与生产体系。在传统创新药需求叠加AI制药增量的共振之下，行业中长期成长空间进一步打开。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989237","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518857.USD","CXO","BK1191","HK0000320264.USD","BK1161","09939","WX","01548","LU0856984785.SGD","02269","BK0239","SG9999002463.SGD","LU0819121731.USD","LU1880383366.USD","BK0132","LU0307460666.USD","03347","06821","SG9999002562.SGD","LU0052750758.USD","BK1589","KURE","LU1720050803.USD","01873","LU0516422366.SGD","LU0456846285.SGD","LU1242518931.SGD","LU0979878070.USD","LU0823426308.USD","LU0516422440.USD","LU1794554557.SGD","159938","LU0039217434.USD","HK0000320223.HKD","002821","BK1515","LU0140636845.USD","LU0181495838.USD","LU0456827905.SGD","LU0359201612.USD","LU0516422952.EUR","LU0516423091.SGD","LU0326950275.SGD","LU0051755006.USD","HK0000306685.HKD","LU0348825331.USD","LU0359202008.SGD","LU0708995583.HKD","BK1610","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275244","title":"创新药突然哑火，什么原因？华宝基金港股通创新药ETF再失半年线，CXO龙头尽墨，机构:四季度继续看好医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275244","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661275244?lang=zh_cn&edition=full","pubTime":"2026-08-24 19:48","pubTimestamp":1787572080,"startTime":"0","endTime":"0","summary":"8月24日，港股深度调整，近期热度较高的医药板块同步走低。100%创新药研发标的——港股通创新药ETF华宝日线连阴，收于半年线下方，全天振幅3.44%，成交3.18亿元。值得一提的是，截至上周，159137在CXO带动连续5周收涨。全链布局创新药，关注两大T+0利器：港股通创新药ETF华宝：被动跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，7成仓位押注研发龙头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-24/doc-inipmnps2837356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","BK1515","BK1574","FLHK","MEDX","09939","WX","BK1161","159938","CXO","IBBQ","159316","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661219033","title":"天风·医药 | AI4S加速科研范式变革，中国CXO有望迎来产业与估值共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2661219033","media":"天风研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661219033?lang=zh_cn&edition=full","pubTime":"2026-08-22 17:00","pubTimestamp":1787389200,"startTime":"0","endTime":"0","summary":"AI制药从模型创新走向干湿闭环，上游科研服务率先迎来需求放量。头部化+新分子+全球化构筑竞争力，CXO板块有望迎来业绩与估值共振。中国CXO全球竞争力持续提升，凭借规模化生产及成本效率优势，全球市场份额仍具提升空间。我们看好创新药融资回暖、AI4S增量需求及全球外包率提升共同驱动中国CXO景气修复，重点关注具备新分子技术平台、干湿闭环能力及全球化产能布局的头部企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzAwMzIzNzcwMg==&mid=2649153755&idx=5&sn=127ad91cbcf60f400d074876ef23f90d&chksm=828fc6fc1429d4147bb3a6df8c3bcd3eef4a76c32b15ef7d913857d6527fd0b1ff368107047f&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660419923","title":"CXO概念有支撑 凯莱英（06821）涨2.27% 金斯瑞生物科技（01548）涨2.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419923","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660419923?lang=zh_cn&edition=full","pubTime":"2026-08-19 10:53","pubTimestamp":1787108028,"startTime":"0","endTime":"0","summary":"金吾财讯 | CCXO概念有支撑，凯莱英 涨2.27%、金斯瑞生物科技涨2.41%、百济神州涨0.63%、方达控股涨0.79%、药明生物涨0.04%爱建证券表示，2026年初以来医药板块的持续回调与行业基本面、产业趋势发生背离，近期众多上市公司推出现金回购和增持方案，反映出对产业未来发展的充足信心，CXO、创新药及相关产业链已率先发力反弹，医药板块中长期布局良机已至。同时，该机构看好高景气CXO、器械出海、脑机接口、AI+医疗等投资机会。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988641","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518931.SGD","WX","BK1588","BK1576","LU0320764599.SGD","LU0039217434.USD","SG9999002463.SGD","KURE","002821","LU0588546209.SGD","LU0228659784.USD","LU0140636845.USD","01521","LU0516422440.USD","LU1688375341.USD","HK0000306685.HKD","LU0828237510.HKD","CXO","LU0348825331.USD","LU0043850808.USD","BK1589","BK1610","LU0572944931.SGD","LU0708995583.HKD","LU0516422366.SGD","LU1719994722.HKD","LU0359202008.SGD","06821","LU0456827905.SGD","LU1770034418.SGD","LU0819121731.USD","LU2328871848.SGD","LU1720050803.USD","BK1191","LU0417516738.SGD","01548","02269","HK0000320223.HKD","LU0181495838.USD","LU0052750758.USD","LU1969619763.USD","BK1500","LU3063872942.SGD","LU0417516902.SGD","LU0128526141.USD","06160","BK0239","LU0359201612.USD","LU0516423091.SGD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490014","title":"国产创新药迎三重业绩拐点 CXO龙头利润与订单同步创出历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660490014?lang=zh_cn&edition=full","pubTime":"2026-08-19 07:25","pubTimestamp":1787095509,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CXO","LNGR","IBBQ","MEDX","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660464424","title":"CXO开启主升浪，药明系、金斯瑞、康龙等集体突破！华宝基金港股通医疗ETF创5个月收盘新高，医疗ETF8天7阳","url":"https://stock-news.laohu8.com/highlight/detail?id=2660464424","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660464424?lang=zh_cn&edition=full","pubTime":"2026-08-18 19:45","pubTimestamp":1787053500,"startTime":"0","endTime":"0","summary":"8月18日，CXO强者恒强，继续领涨医疗板块！场内高CXO含量ETF继续上行，港股通医疗ETF华宝标的指数CXO含量全市场第一，场内价格续涨1.25%创5个月收盘新高！全市场规模最大医疗ETF华宝CXO含量超30%，斩获8天7阳。药明康德半年度净利润历史首次突破百亿元大关，并大幅上调全年指引；康龙化成Q2收入和经调利润分别同比增长19.38%和22.3%；昭衍新药上半年归母净利润同比预增884.9%至1377.4%。其中药明系占比超38%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-18/doc-inintxxh8569801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CXO","WX","FLHK","159828"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660138101","title":"CXO再度爆发，药明康德H股叒新高！华宝基金港股通医疗ETF（159137）上探3.5%，标的指数CXO含量全市场第一","url":"https://stock-news.laohu8.com/highlight/detail?id=2660138101","media":"新浪基金","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660138101?lang=zh_cn&edition=full","pubTime":"2026-08-17 11:19","pubTimestamp":1786936740,"startTime":"0","endTime":"0","summary":"8月17日，港股通医疗板块强势反弹，CXO再度领涨，药明康德港股再创历史新高！场内热门ETF方面，可T+0交易的港股通医疗ETF华宝盘中上探3.5%收复5日线！数据显示，其标的指数CXO含量达52.5%，在全市场可投资指数中为最高，其中药明系权重占比超38%，同样高居首位。最新CXO含量达32.82%，其中药明康德（A股）占比13.42%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-17/doc-ininqtns0348637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2495084118.USD","LU0469268626.HKD","IE00BPRC5H50.USD","CXO","LU0052750758.USD","LU0708995583.HKD","LU1303224171.USD","603259","LU0572944931.SGD","LU1770034418.SGD","BK1583","LU1997245094.SGD","LU1808992512.USD","LU1251922891.USD","LU0320764599.SGD","LU0348766576.USD","LU1719994722.HKD","LU2328871848.SGD","IE00B5MMRT66.SGD","159828","LU0700851271.USD","02359","LU1046422090.SGD","LU2045819591.USD","BK1141","BK1576","BK0216","LU2125910500.SGD","159137","LU0611395673.USD","LU1979443071.USD","LU1997244956.HKD","LU1997245177.USD","LU0456842615.SGD","LU2488822045.USD","LU0348767384.USD","LU0327786744.USD","LU1969619763.USD","LU1934453819.USD","LU2242644610.SGD","WX","IE00B543WZ88.USD","FLHK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660810134","title":"强业绩引爆CXO行情，哪个可投资指数CXO含量最高？","url":"https://stock-news.laohu8.com/highlight/detail?id=2660810134","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660810134?lang=zh_cn&edition=full","pubTime":"2026-08-17 11:03","pubTimestamp":1786935780,"startTime":"0","endTime":"0","summary":"🔥药明康德交出史上最强中报🚀CXO行业景气上行持续验证一键投资CXO，关注T+0利器👇🏻🔥港股通医疗ETF华宝#159137❤️标的指数CXO含量52.5%，全市场第一❗💙其中药明系权重占比超38%🐲投龙头·选华宝⚠️市场有风险，投资须谨慎","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-17/doc-ininqtnu9181150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659612294","title":"订单饱满结构升级 CXO企业半年度业绩释放回暖信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2659612294","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659612294?lang=zh_cn&edition=full","pubTime":"2026-08-15 07:30","pubTimestamp":1786750211,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CXO","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659187744","title":"CXO强者恒强！药明康德AH股齐升，皓元医药涨超8%！华宝基金医疗ETF（512170）涨超2%冲击五连阳","url":"https://stock-news.laohu8.com/highlight/detail?id=2659187744","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659187744?lang=zh_cn&edition=full","pubTime":"2026-08-13 11:25","pubTimestamp":1786591500,"startTime":"0","endTime":"0","summary":"8月13日，AH医疗板块迅速反弹。CXO强者恒强，药明康德AH股双双涨逾1%，康龙化成AH股齐升逾4%，A股皓元医药涨超7%。场内高CXO含量ETF同步走走强，CXO含量超50%的港股通医疗ETF华宝涨逾1%。全市场规模最大医疗ETF华宝CXO含量超30%，盘中涨超2%冲击五连阳，成交超4.5亿元。紧跟医疗反攻行情，关注两大“利器”：港股通医疗ETF华宝：最新CXO含量达51.88%，其中药明系权重占比超38%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-13/doc-ininctaw3414344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1576","688131","LU0052750758.USD","IE00B5MMRT66.SGD","LU0348766576.USD","LU1303224171.USD","LU1046422090.SGD","LU2495084118.USD","LU0700851271.USD","LU2242644610.SGD","LU1808992512.USD","LU0708995583.HKD","BK1141","603259","LU2488822045.USD","LU0320764599.SGD","LU1719994722.HKD","LU1997245094.SGD","BK0216","LU0348767384.USD","LU2045819591.USD","LU2125910500.SGD","LU1934453819.USD","CXO","IE00BPRC5H50.USD","LU1251922891.USD","LU0456842615.SGD","LU1997244956.HKD","512170","LU1969619763.USD","WX","LU0611395673.USD","159828","LU1770034418.SGD","LU2328871848.SGD","BK1583","02359","LU1979443071.USD","IE00B543WZ88.USD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659182702","title":"美银证券：中国CXO行业受惠生物科技融资强劲 上调药明康德(02359)等目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2659182702","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659182702?lang=zh_cn&edition=full","pubTime":"2026-08-13 10:20","pubTimestamp":1786587659,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研报称，受惠上半年全球及中国生物科技一级市场融资表现强劲，加上创新药对外授权交易持续活跃，预期研发活动将进一步加快，中国CRO/CDMO企业可望受惠。该行上调药明康德H股目标价由204.3港元至242港元，药明康德A股目标价由177.8元人民币至210.5元人民币，维持“买入”评级，因其增长能见度清晰。该行并上调药明康德2029至2035年收入估算介乎3%至7%，经调整纯利预测亦上调介乎3%至7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BBC","SMCO","LFSC","PSIL","BMED","161027","MEDI","CXO","FHLC","IBRN","IDNA","SURI","WX","APXH","PSCH","02359","603259","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658288069","title":"医药调研热度超越半导体！创新药回调，华宝基金港股通创新药ETF失守半年线！CXO韧性十足，药明系逆市飘红","url":"https://stock-news.laohu8.com/highlight/detail?id=2658288069","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658288069?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:02","pubTimestamp":1786503720,"startTime":"0","endTime":"0","summary":"业绩兑现叠加AI制药概念加持，CXO韧性十足，药明生物、药明康德、药明合联逆市飘红，金斯瑞生物科技续涨逾1%。港股通创新药龙头股批量飘绿，百济神州跌2%止步6连阳，翰森制药跌逾3%；再鼎医药延续涨势，股价创年内新高。100%创新药研发标的——港股通创新药ETF华宝冲高回落，现跌1%再失半年线。8月以来，创新药及产业链利好密集，“吃药”行情持续上演。同期医药生物行业的市场关注度大幅攀升。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-12/doc-inimzqcp6895872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SMHX","159582","CHPY","MEDX","TEKX","USD","MQQQ","SOXQ","TECY","06978","WX","SSG","SOXS","IBBQ","LNGR","159992","BK4535","NBDS","PSI","SMHU","FLHK","BK1515","VGT","SOXX","BK1161","CXO","SMH","SOXL","CHPS","FTXL","CWC","XSD","09939","EIS","BK1574","159938","BK4585","BK4588","159316","SOXY","FWD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657698357","title":"港股CXO近日股价集体走高，盈警之后的泰德医药(03880)将逆市下跌还是超跌反弹？","url":"https://stock-news.laohu8.com/highlight/detail?id=2657698357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657698357?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:22","pubTimestamp":1786069332,"startTime":"0","endTime":"0","summary":"7月31日盘后，泰德医药发布了其26H1财年盈警公告。目前泰德医药尚未迎来连续数个交易日的低点逐步抬高以彻底终结下跌趋势，关键的量能均线也尚未出现明显转折。近日，港股医药概念股集体走高，CXO、创新药板块多点爆发，带动恒生医疗保健指数强势反弹。以8月4日行情为例，港股CXO板块出现一波个股集体走高，其中药明康德股价大涨11.17%，康龙化成和泰格医药均涨超5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","03880","WX","NIFE","BK1141","KCAI","VXUS","CXO","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657002","title":"【券商聚焦】中信建投：CXO 行业复苏明确，海内外医药投融资同步回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657002","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657657002?lang=zh_cn&edition=full","pubTime":"2026-08-06 09:04","pubTimestamp":1785978243,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投表示，国内CXO行业经历22-24年的调整阶段后，受益海外投融资率先回暖，24年国内头部CXO公司海外订单展现复苏态势，随着25年国内创新药资产实现大规模对外授权，带动国内投融资25H2持续复苏，行业内需同样企稳回升。26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该机构认为26年国","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987586","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CXO","601066","KCE","159938","BK0276","BK1515","09939","BK1574","BK1161","WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572212","title":"中信建投：CXO板块Beta稳中向好，AI制药大有可为","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572212","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657572212?lang=zh_cn&edition=full","pubTime":"2026-08-06 07:41","pubTimestamp":1785973273,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CHAT","CXO","AIPO","VTHR","AGIX","WX","QTOC","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657591587","title":"CXO巨头爆量上涨！开盘45分钟成交120亿元，超上日全天！规模最大医疗ETF（512170）创本轮反弹新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2657591587","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657591587?lang=zh_cn&edition=full","pubTime":"2026-08-05 10:35","pubTimestamp":1785897300,"startTime":"0","endTime":"0","summary":"CXO巨头药明康德重磅财报继续发酵！8月5日早盘，药明康德A股爆量上行，盘初一度续涨逾6%，截至10：15涨4.6%，成交超120亿元，超越上日全天，跻身A股成交额前五！全市场规模最大医疗ETF华宝同步上扬，场内价格创本轮反弹新高！数据显示，药明康德为医疗ETF华宝第一大重仓股，最新持仓占比达12.69%。高效参与CXO交易，关注两大“利器”：医疗ETF华宝：全市场规模最大医药医疗类ETF，聚焦医疗器械+医疗服务，兼顾AI医疗概念。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-05/doc-inimfshm5200987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","512170","CXO","159828"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656158919","title":"港股异动 | CRO概念股涨幅居前 近期多家海外MNC与CXO披露中报盈喜并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2656158919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656158919?lang=zh_cn&edition=full","pubTime":"2026-08-04 11:05","pubTimestamp":1785812703,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股涨幅居前，截至发稿，药明康德涨11.05%，报180.9港元；金斯瑞生物科技涨10.18%，报17.96港元；凯莱英涨7.71%，报117.4港元；药明生物涨3.92%，报40.34港元。消息面上，药明康德公告称，上半年公司实现营业收入288.97亿元，同比增长38.93%；归母净利润110.8亿元，同比增长29.43%。值得注意的是，近期已有多家多家海外MNC与CXO披露中报盈喜并上调全年指引。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01548","VXUS","HK0000306701.USD","LU0456846285.SGD","BK1583","02359","LU1794554557.SGD","BK1610","LU0456827905.SGD","LU1046422090.SGD","LU0359202008.SGD","LU0417516902.SGD","BK4588","LU1242518857.USD","BK1589","LU1242518931.SGD","KURE","LU0588546209.SGD","LU0348766576.USD","LU0039217434.USD","KCAI","BK1576","LU0140636845.USD","SG9999002463.SGD","LU0052750758.USD","02269","LU0516423174.USD","LU1720050803.USD","LU0516422952.EUR","LU0348825331.USD","LU0327786744.USD","LU0856984785.SGD","LU0979878070.USD","BK4585","LU0417516738.SGD","LU3063872942.SGD","BK1191","LU0823426480.USD","WX","LU0708995583.HKD","LU1688375341.USD","LU0181495838.USD","CXO","BK1521","LU0516422440.USD","HK0000306685.HKD","06821","LU0348767384.USD","BK1141","LU0043850808.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.concho.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0547},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1215},{"period":"1year","weight":0.1856},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Concho Resources Inc.成立于2006年2月22日，是一家于2006年2月在特拉华州注册成立的公司，是一家独立的石油和天然气公司，从事石油和天然气资产的收购、开发、勘探和生产。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.054246},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.002949},{"month":3,"riseRate":0.692308,"avgChangeRate":0.024071},{"month":4,"riseRate":0.769231,"avgChangeRate":0.069872},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.030229},{"month":6,"riseRate":0.461538,"avgChangeRate":0.004495},{"month":7,"riseRate":0.692308,"avgChangeRate":0.012949},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.02419},{"month":9,"riseRate":0.571429,"avgChangeRate":0.015298},{"month":10,"riseRate":0.5,"avgChangeRate":0.017047},{"month":11,"riseRate":0.571429,"avgChangeRate":0.047858},{"month":12,"riseRate":0.642857,"avgChangeRate":0.007299}],"exchange":"NYSE","name":"康休","nameEN":"Concho Resources"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康休,CXO,康休股票,康休股票老虎,康休股票老虎国际,康休行情,康休股票行情,康休股价,康休股市,康休股票价格,康休股票交易,康休股票购买,康休股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}